Advancements in Gene Therapy Investment
According to reports from Endpoints News, life sciences investor Syncona has launched a new gene therapy company named Purespring. Spun out of the University of Bristol, Purespring has secured a Series A financing round of approximately $60 million (£45 million). While focusing on a different complex solid organ, developments in targeted gene delivery platforms represent notable movement within the broader gene therapy and rare disease therapeutic landscape.
Key Details of the Launch
Purespring is built upon the research of Moin Saleem, a professor of pediatric renal medicine at the University of Bristol, who has focused on addressing challenges in targeting genetic material to specific cell types within complex solid organs. Additionally, the company will utilize FunSel, an in vivo screening platform developed by researchers at King's College London, to screen for cell-specific protective factors.
Syncona has committed a £45 million Series A investment, representing an initial tranche with plans to hold an 84 percent stake in the business. Syncona Chief Investment Officer Chris Hollowood has been named chairman, and Syncona Partner Dominic Schmidt will join the board of directors.
Broad Implications for Genetic Medicine
Although Purespring’s initial focus is directed toward chronic kidney diseases, innovations in AAV gene delivery systems and target discovery platforms carry broad implications for the wider genetic disease community. Overcoming the hurdles of precise cellular targeting in complex organs remains a shared objective across many fields exploring gene-based interventions.
Looking Ahead
With its Series A funding secured, Purespring plans to use the capital to build out its operations, advance its platform, and support its progression toward clinical-stage development.